Report : North America Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application [Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Others], and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)
Enoxaparin Segment to Dominate North America Low Molecular Weight Heparin Market during 2019–2028
According to a new market research study on “North America Low Molecular Weight Heparin Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Packaging, Application, and End User,” is expected to reach US$ 1,963.46 million by 2028 from US$ 1,232.86 million in 2021. The market is estimated to grow at a CAGR of 6.9% from 2021 to 2028. Introduction of LMWH anticoagulants is the major factor driving the growth of the North America low molecular weight heparin market. However, adverse effects of low molecular weight heparin during treatment may hinder the growth of North America low molecular weight heparin market. The report provides trends prevailing in the North America low molecular weight heparin market along with the drivers and restraints pertaining to the market growth.
North America is highly affected due to the COVID-19 pandemic. This led to increased demand for diagnosing and therapeutic devices in hospitals. The FDA has increased its efforts to provide healthcare to people and has imposed several guidelines for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. Despite facing the ill effects of SARS and H1N1 outbreaks in the last few years, the severity of the COVID-19 pandemic made the situation more complicated for the healthcare sectors due to its mode of transmission. The ongoing pandemic is straining public health systems globally, interrupting and delaying critical healthcare procedures. As per the IRI data, demand for various dietary supplements grew after the onset of the COVID-19 pandemic in the US at unprecedented rates. The total supplement sales increased by 6% during the first week of March 2020.
The North America low molecular weight heparin market is segmented into product type, packaging, application, end user and country. The North America low molecular weight heparin market, based on product type, has been segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. The North America low molecular weight heparin market based on packaging is segmented into multi-vials and prefilled syringes. In 2021, the multi-vials segment held the largest share of the market. The North America low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. The North America low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. Similarly, based on country, the market is bifurcated into US, Canada, and Mexico. The US held the largest share of the North America low molecular weight heparin market in 2021.
Abbott, Aspen Holdings, B. Braun Medical Inc., Dr. Reddy's Laboratories, LEO Pharma A/S, Novartis, Pfizer Inc., Sanofi, and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the North America Low Molecular Weight Heparin Market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2019, The US Food and Drug Administration (FDA) has approved the use of Pfizer's anticoagulant medicine Fragmin (dalteparin sodium) to minimise the recurrence of symptomatic venous thromboembolism (VTE) in paediatric patients aged one month and above.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com